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occurred more frequently in women than in men (46% v 33%, p=0.05) and in patients who achieved remission after medical treatment than after surgery (46% v 25%, p=0.02). Relapse was also associated with smoking status (current smokers 53%, former smokers 35%, non-smokers 30%; p=0.02) and oral contraceptive use (current use 43%, previous use 70%, no use 27%; p<0.001). Multivariate analysis showed that an increased risk of relapse was associated with current smoking, previous or current oral contraceptive use, and medical induction of remission; sex and previous smoking were not associated with an increased risk of relapse (table) . No interaction between smoking and oral contraceptive use occurred.
Conclusion
Current smoking, previous or current oral contraceptive use, and medical induction of remission were independent risk factors for relapse in patients with Crohn's disease in remission. 
Commentary
Epidemiological studies reporting positive associations between smoking and oral contraceptives (OC) and Crohn's disease first appeared in the mid-1980s. Subsequently neither association has been found to be especially strong (relative risks around 3 for smoking and 2 for OC) and there continues to be uncertainty as to whether or not these are causal associations. 1 Smoking and OC use also confound one another, with OC use being more common in smokers.
In contrast to the association between Helicobacter pylori and duodenal ulcer, it is not possible to test the reversibility of the associations by randomised trials. A less rigorous test of causation is to observe the relations between these factors and prognosis of Crohn's disease as Timmer et al have done. Examining prognosis in the context of a controlled trial has several attractions-prospective data recording, minimal problems of misclassification and unbiased assessment of outcome.
Their twofold increase in relapse rate for current smokers is consistent with earlier retrospective studies. The relapse rate is less well-established in ex-smokers. Retrospective assessment of ex-smoking presents obvious diYculties. The one previous prospective study involved only 23 ex-smokers and found rates similar to never smokers. 2 Timmer et al's identical finding not only strengthens the evidence of reversibility but should buttress our eVorts to persuade smokers with Crohn's disease to stop. 3 Although their findings on smoking are reassuring and unlikely to excite debate, the OC use results are much less clear cut and likely to be controversial. The total number of women is modest (88 women) and the decision to restrict (commentary continued from page 311) analysis to women aged 18-55 reduces the numbers further. Including all the patients randomised (to mesalazine as well as placebo) would have increased the numbers but as there was a statistically significant interaction between treatment and OC use they were unable to do this. The threefold increase in the relapse rate of OC users is predominantly accounted for by a high rate in ex-users which is much greater than the rate in current users, which alone was not statistically significant. Indeed, figure 2 shows that the univariate relapse rate at 48 weeks in their 17 ex-OC users was >70% compared with <50% in 28 current OC users and <30% in 30 never users. It is implausible that a causal relation should be stronger in ex-users than current users. Furthermore, ex-use is not described so it is unclear what proportion have not taken OC for several years. In the two British cohort studies of OC use ex-users had the same risk of Crohn's disease as never users. 4 Clearly, more data are needed, possibly from other trials of maintenance treatment. As yet, there is insuYcient evidence to advise patients with Crohn's disease to stop taking OC but if asked, advice not to start taking OC might be prudent. 
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